Thomas Weisel Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Overweight
IDIX Hot Sheet
Rating Summary:5 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 7 | New: 22
Thomas Weisel initiates coverage on Idenix Pharmaceuticals (Nasdaq: IDIX) with an Overweight rating. Price target $8.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Evercore Partners Starts Golar LNG Ltd. (GLNG) at Overweight
- Wunderlich Securities Starts United Stationers (USTR) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Thomas Weisel Partners GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
